179 related articles for article (PubMed ID: 25673055)
1. 3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.
Challapalli A; Barwick T; Pearson RA; Merchant S; Mauri F; Howell EC; Sumpter K; Maxwell RJ; Aboagye EO; Sharma R
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):831-40. PubMed ID: 25673055
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
Herrmann K; Erkan M; Dobritz M; Schuster T; Siveke JT; Beer AJ; Wester HJ; Schmid RM; Friess H; Schwaiger M; Kleeff J; Buck AK
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):846-51. PubMed ID: 22278320
[TBL] [Abstract][Full Text] [Related]
3. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
4. Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.
Contractor K; Challapalli A; Tomasi G; Rosso L; Wasan H; Stebbing J; Kenny L; Mangar S; Riddle P; Palmieri C; Al-Nahhas A; Sharma R; Turkheimer F; Coombes RC; Aboagye E
Phys Med Biol; 2012 Jun; 57(11):3419-33. PubMed ID: 22572708
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of
Sharma R; Mapelli P; Hanna GB; Goldin R; Power D; Al-Nahhas A; Merchant S; Ramaswami R; Challapalli A; Barwick T; Aboagye EO
EJNMMI Res; 2016 Dec; 6(1):81. PubMed ID: 27854031
[TBL] [Abstract][Full Text] [Related]
6. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
[TBL] [Abstract][Full Text] [Related]
8. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
Contractor KB; Kenny LM; Stebbing J; Challapalli A; Al-Nahhas A; Palmieri C; Shousha S; Lewis JS; Hogben K; De Nguyen Q; Coombes RC; Aboagye EO
Nucl Med Commun; 2011 Nov; 32(11):997-1004. PubMed ID: 21862943
[TBL] [Abstract][Full Text] [Related]
9. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
[TBL] [Abstract][Full Text] [Related]
10. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
[TBL] [Abstract][Full Text] [Related]
12. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
13. Correlation of
Wilson JM; Mukherjee S; Brunner TB; Partridge M; Hawkins MA
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):370-377. PubMed ID: 28190636
[TBL] [Abstract][Full Text] [Related]
14. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT.
Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Nihara T; Fukukura Y; Yoshiura T
Abdom Radiol (NY); 2017 Apr; 42(4):1210-1221. PubMed ID: 27891549
[TBL] [Abstract][Full Text] [Related]
16. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
Crippa F; Agresti R; Sandri M; Mariani G; Padovano B; Alessi A; Bianchi G; Bombardieri E; Maugeri I; Rampa M; Carcangiu ML; Trecate G; Pascali C; Bogni A; Martelli G; de Braud F
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):818-30. PubMed ID: 25673053
[TBL] [Abstract][Full Text] [Related]
19. Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine.
Paproski RJ; Young JD; Cass CE
Biochem Pharmacol; 2010 Feb; 79(4):587-95. PubMed ID: 19788890
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma.
Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T
Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
